AxoGen Inc
NASDAQ:AXGN
AxoGen Inc
NASDAQ:AXGN
Price:
6.06 USD
3.24%
Updated:
May 9, 2024
P/B
Price to Book Value
Price to Book Value
2.8
Current
3.9
Median
2.3
Industry
Lower
than median
Higher
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=2.8
Market Cap
/
256.9m
Book Value of Equity
93.2m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| US |
|
AxoGen Inc
NASDAQ:AXGN
|
256.9m USD | 2.8 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
182.5B USD | 4.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
136.9B USD | 9.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.3B USD | 6.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.5B USD | 2.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
108.6B USD | 5.4 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.8B USD | 2.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
58.5B EUR | 3.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
52.6B USD | 7.3 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
367.2B CNY | 10 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
51.1B USD | 22.7 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
